Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

65.39
+2.373.76%
Volume:284.04K
Turnover:18.55M
Market Cap:1.88B
PE:-142.12
High:66.01
Open:64.06
Low:64.00
Close:63.02
52wk High:68.39
52wk Low:15.40
Shares:28.75M
Float Shares:17.26M
Volume Ratio:0.36
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4601
EPS(LYR):-0.4601
ROE:-24.49%
ROA:7.06%
PB:50.52
PE(LYR):-142.12

Loading ...

Truist Securities Adjusts AnaptysBio Price Target to $36 From $20, Maintains Hold Rating

MT Newswires Live
·
Nov 10, 2025

AnaptysBio Is Maintained at Buy by Guggenheim

Dow Jones
·
Nov 05, 2025

AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales

Reuters
·
Nov 05, 2025

BRIEF-AnaptysBio Q3 Net Income USD 15.113 Million

Reuters
·
Nov 05, 2025

AnaptysBio Inc : Leerink Partners Raises Target Price to $62 From $51

THOMSON REUTERS
·
Oct 29, 2025

AnaptysBio Reports Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

Reuters
·
Oct 29, 2025

AnaptysBio Inc - Rosnilimab Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Oct 29, 2025

AnaptysBio Inc - Rosnilimab Shows Efficacy in Ra With Cdai Remission

THOMSON REUTERS
·
Oct 29, 2025

Anaptys Announces New Positive Phase 2B Trial Results for Rosnilimab in Rheumatoid Arthritis at Acr Late-Breaking Oral Presentation

THOMSON REUTERS
·
Oct 29, 2025

Wedbush Raises Price Target on AnaptysBio to $70 From $45, Keeps Outperform Rating

MT Newswires Live
·
Oct 15, 2025

AnaptysBio price target raised to $70 from $45 at Wedbush

TIPRANKS
·
Oct 15, 2025

U.S. RESEARCH ROUNDUP-Applovin, Caterpillar, ESAB

Reuters
·
Oct 14, 2025

AnaptysBio Inc : Piper Sandler Raises Target Price to $72 From $57

THOMSON REUTERS
·
Oct 14, 2025

AnaptysBio to Present Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at ACR Convergence 2025

Reuters
·
Oct 13, 2025

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2B Data for Rosnilimab in Rheumatoid Arthritis at Upcoming Acr Convergence 2025

THOMSON REUTERS
·
Oct 13, 2025

AnaptysBio :  Barclays Initiates Coverage With Overweight Rating and Target Price $78

THOMSON REUTERS
·
Oct 13, 2025

Barclays Initiates AnaptysBio at Overweight With $78 Price Target

MT Newswires Live
·
Oct 13, 2025

AnaptysBio Initiated at Overweight by Barclays

Dow Jones
·
Oct 13, 2025

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Certara (CERT)

TIPRANKS
·
Oct 09, 2025

Eric J. Loumeau, Chief Legal Officer, Reports Disposal of AnaptysBio Inc. Common Shares

Reuters
·
Oct 02, 2025